Atezolizumab (Tecentriq) ELISA Assay Kit
For Research Use Only
Size: 12×8 wells
Dynamic Range: 2.5 – 160ng/mL
Sensitivity: 2.5 ng/mL
Incubation Time: 2.5 hours
Sample Type: Serum, Plasma, Cell Culture Supernatants
Sample Size: 100 µL
Atezolizumab (Tecentriq) ELISA Assay Kit
$740.00
The Eagle Biosciences Atezolizumab (Tecentriq) ELISA is used as an analytical tool for quantitative determination of Atezolizumab in serum, plasma, and cell culture supernatants.
Additional Information
Assay Background
Atezolizumab (trade name Tecentriq) is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1). In 2015, it was in clinical trials as an immunotherapy for several types of solid tumors. It was under investigation by Genetech/Roche. In April 2016, Roche announced that atezolizumab had been granted fast track status for lung cancer by the FDA. In May 2018, Tecentriq was in combination with Avastin and standard chemotherapy for some patients with lunch cancer was granted priority review.
Assay Principle
The method employs the quantitative sandwich enzyme immunoassay technique. Antibodies to Atezolizumab are pre-coated onto microwells. Samples and standards are pipetted into microwells and human Atezolizumab present int he sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated anti-Atezolizumab antibody is pipetted and incubated. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Atezolizumab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.
